Comment
Definition and management of radioactive iodine-refractory differentiated thyroid cancer

https://doi.org/10.1016/S2213-8587(13)70215-8Get rights and content

First page preview

First page preview
Click to open first page preview

References (10)

  • MM Xing et al.

    Progress in molecular-based management of differentiated thyroid cancer

    Lancet

    (2013)
  • C Durante et al.

    Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy

    J Clin Endocrinol Metab

    (2006)
  • MM Sabra et al.

    Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans

    Thyroid

    (2012)
  • G Sgouros et al.

    Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software

    J Nucl Med

    (2004)
  • RJ Robbins et al.

    Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning

    J Clin Endocrinol Metab

    (2006)
There are more references available in the full text version of this article.

Cited by (263)

  • Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities

    2023, Biochimica et Biophysica Acta - Reviews on Cancer
View all citing articles on Scopus
View full text